Dedicated to Discovering Breakthroughs for Complicated Diseases

Clinical Trials

Clinical trials are vital to driving innovation and advancing science that improves patient lives.
Learn more about SalubrisBio’s clinical trials and how to participate.

JK07 in HFrEF

Enrollment is completed in the ongoing Phase 1b portion of the trial evaluating JK07, an NRG1-HER3 antibody fusion protein, in NYHA II/III heart failure patients with reduced ejection fraction. Phase 2 of the study is expected to begin in the second half of 2023

Check back soon for more details.

JK07 in HFpEF

Recruitment is ongoing in the Phase 1b clinical trial assessing the safety and tolerability of JK07 in adults with heart failure patients with preserved ejection fraction.

Solid Tumor Cancers

The first-in-human trial of JK08, an immunocytokine fusion protein comprised of IL15 and a CTLA-4 targeted antibody, in adults with solid tumors is underway and currently enrolling patients for the Phase 1b/2 portion of the program.


We anticipate initiating our first neurology clinical trial in ALS, or amyotrophic lateral sclerosis, in 2023.

Check back soon for more details.